3,217 reports of this reaction
3.3% of all VENETOCLAX reports
#3 most reported adverse reaction
NEUTROPENIA is the #3 most commonly reported adverse reaction for VENETOCLAX, manufactured by AbbVie Inc.. There are 3,217 FDA adverse event reports linking VENETOCLAX to NEUTROPENIA. This represents approximately 3.3% of all 98,823 adverse event reports for this drug.
VENETOCLAX has an overall safety score of 88 out of 100. Patients taking VENETOCLAX who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among VENETOCLAX users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for VENETOCLAX:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 3,217 FDA reports for VENETOCLAX. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 3.3% of all adverse event reports for VENETOCLAX, making it one of the most commonly reported side effect.
If you experience neutropenia while taking VENETOCLAX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.